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The cost-effectiveness of intensive patient education of guided asthma self-management given during the first
treatment year was evaluated after 5 years of follow-up. Consecutive, newly-diagnosed asthmatics (n=162, age
18–76 years) were randomized for intensive (80 patients) vs. conventional patient education. Effectiveness was
evaluated in terms of lung functions, airway hyperresponsiveness (PD15), and quality of life as measured by the
generic 15D and disease-specific St. George’s Respiratory Questionnaire (SGRQ). Total treatment costs were also
estimated. All patients had anti-inflammatory treatment from the beginning. Sixty-four intervention group (IG)
patients and 70 control group (CG) patients were evaluated after 5 years. Forced expiratory volume in 1 sec (FEV1)
improved only in the IG, and only during the first treatment year. However, PD15 improved throughout the follow-
up. The unscheduled healthcare costs were significantly higher in the CG than in the IG (P=0?04) and the relative
risk for sickness days due to asthma was lower in the IG than in the CG, odds ratio 0?33 (95% CI 0?28; 0?40).
However, because there was no significant difference between the groups in any outcome variable or in total costs at
5 years, the incremental cost-effectiveness ratio could not be calculated. The first year intervention had only a short-
term beneficial treatment effect, which the CG could catch up during the two last follow-up years, except in FEV1.
The peak expiratory flow (PEF)-based self-management had no advantage over the symptom-based self-
management. However, the intervention had a consistent tendency of being less costly in the long-run. It is possible
to conclude tentatively that regular effective medical treatment and control visits during the first treatment year is at
least as important for the long-term treatment result as intensive patient education.
Key words: patient education and economics; asthma quality of life; self-management and asthma and economics;
asthma therapy and economics.
RESPIR. MED. (2001) 95, 56–63 # 2001 HARCOURT PUBLISHERS LTD
RESPIRATORY MEDICINE (2001) 95, 56–63
doi:10.1053/rmed.2000.0971, available online at http://www.idealibrary.com onIntroduction
Patient education and self-management have had an
economic impact among mild, moderate or severe asth-
matics in terms of reducing the use of healthcare services,
but less of an impact on improving lung function (1–3).
However, the findings regarding the effectiveness of
different methods for implementing patient education and
self-management plans are controversial (4–8). Chapman
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of education studies (9).
Self-management was concluded to reduce unscheduled
hospital or physician visits and days off from work or
school in the Cochrane review, which included no long-
term studies concerning self-management education for
newly-diagnosed asthmatics (10). When the costs of
intervention for patient education during the first treatment
year are considered, there appear to be no economic
benefits during the first 3 years from such an intervention
(11,12).
The aim of the present study was to evaluate the
effectiveness of intensive patient education for self-manage-
ment given during the first treatment year in terms of
asthma progression and quality of life, and evaluate the
treatment costs over a follow-up period of 5 years among
newly-diagnosed asthmatics.
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FIG. 1. The study plan. |=Visit to the outpatient clinic
for the intervention education; * a group education
between 6 and 9 months, two or three asthmatics together.
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The 162 consecutive, newly-diagnosed adult (over 16 years)
asthmatic patients were recruited from the outpatient clinic
of South Karelia Central Hospital. They were diagnosed
according to the criteria of the American Thoracic Society
(13). All agreed 1 month later to be randomized into
intensive patient education and follow-up during the first
treatment year (intervention group IG), or into a control
group (CG). At baseline the IG consisted of 80 patients, of
whom 64 (25 men) were evaluated at 5 years. The CG
consisted of 82 patients at baseline, and 70 (27 men) were
evaluated at 5 years. The patient characteristics at baseline
are given in Table 1.
The Hospital Ethical Committee approved the study plan
(Fig. 1) and informed consent was obtained from all patients.
The details of the programme, treatments and outcome
measures during follow-up and the calculation of direct and
indirect costs have been published previously (11,12).
THE BASIC EDUCATION PROGRAMME
FOR ALL PATIENTS
The conventional patient education programme covered the
use of inhaled drugs, PEF monitoring and principles of
treatment. Two respiratory nurses, earlier trained in the
hospital to give patient education in the outpatient clinic,
were also trained to conduct this programme. At the
randomization visit, the patients were shown a video on
asthma and instructed in self-management by the chest
physician, who explained the principles and importance of
self-management and wrote their personal instructions in a
diary according to the plan described below. This basic
education package was administered to both patient groups
during the visits for diagnosis and randomization.
TREATMENT OF ALL PATIENTS
Treatment followed the normal protocol in the clinic, all
patients being routinely prescribed inhaled anti-inflamma-
tory treatment. The mean prescribed daily maintenance
doses were 1?01mg beclomethasone, 0?97mg budesonide
and 11 mg nedocromil in the intervention group, and
1.03mg beclomethasone, 0?97mg budesonide and 10 mg
nedocromil in the control group. The patients themselves
were responsible for buying their drugs. For the first 2
months the doses of anti-inflammatory drugs were doubled
compared with the prescribed maintenance doses as
explained earlier (11,12).
SELF-MANAGEMENT PLAN
A peak-flow meter and a diary were given to all participants
for the first year and after that they were asked to buy their
own PEF meter. Patients were asked to monitor their PEF
values during the first year for at least 2 weeks every third
month, and to record the values in the diary and later to
check their PEF at least once a month in the morning. They
were also asked to monitor PEF for 2 weeks before thecontrol visits and whenever symptoms appeared. This plan
was similar to that later adopted in the Finnish asthma
programme (14).
Both groups recorded in the diary the use of extra
healthcare services, extra medication and sickness days due
to asthma.
The patient was defined as a complier if he or she had
used the PEF meter at least once a month, during the
symptoms, and for at least 6 days before the follow-up visit.
Advice was given when to change the medication, to
contact their general practitioner or to go the emergency
department (12).
THE INTERVENTION
The extra education beyond that received by the CG was
given in the clinic every third month during the first year. It
included the repetition of self-management instructions,
principles of asthma treatment and use of drugs. The nurse
used in total an average of 1?5 h per patient for this
education and arranging appointments. The intervention
included also a 2-h education programme for all IG
patients between the visits at 6 and 9 months. Two or
three asthmatic patients attended at a time. A physiothera-
pist and two nurses gave the education; one specialized in
social affairs and the other in rehabilitation (Fig. 1).
OUTCOME MEASURES
Clinical measurements at baseline and at 12, 36 and 60
months were performed at least 12 h after the latest use of
bronchodilating drugs, as explained earlier (12). Peak
expiratory flow was measured with Wright’s PEF meter
(Clement Clarke International Ltd., England) during the
visits. Normal Finnish spirometric and Nunn’s PEF values
were used (15,16). The results are given as percentages of
normal values. The severity of asthma was defined on the
basis of FEV1 level. Airway responsiveness was measured
as the provocative dose of histamine required causing a
15% fall in FEV1 (PD15) (12,17). At baseline the airway
responsiveness and spirometric values were measured
before any use of inhaled anti-inflammatory drugs.
Health-related quality of life (HRQOL) was measured
by the generic 15D (18), and the disease-specific St.
George’s Respiratory Questionnaire (SGRQ) (19,20). Both
58 R. KAUPPINEN ET AL.instruments have been used earlier among Finnish asth-
matic patients (11,21).
At the 5-year evaluation, the new short version of the
SGRQ with 20 items was also used (AQ20). The response to
each item is in the form of yes, no or not applicable. The
score equals the number of the positive responses (0=best,
20=worse) (22). The English version of the short
questionnaire was first translated into Finnish, and then
translated back to English and from that version once again
to Finnish by a translator fluent in Finnish and English.
COSTS
The use of asthma medication (inhaled corticosteroid,
cromons, bronchodilators and theophyllin) was evaluated
by collecting the data on bought and reimbursed drugs from
the Finnish Social Insurance Institution. This information
was available only after the first treatment year. Any extra
drugs used for asthma treatment (oral corticosteroids and
antibiotics) were valued at average retail prices.
The costing of patient education including the visits to
the outpatient clinic, inpatient days and emergency visits
was based on the all-inclusive (labour, capital, maintenance
etc.) unit costs prevailing in South Karelia Central Hospital
in 1993 as explained earlier (11,12).
The main results are presented undiscounted. As a form
of sensitivity analysis the difference between the groups in
total costs is also reported, discounted at 3% and 6%.
The average annual costs were calculated by including
the costs of all patients so long as they remained in the
study. The costs of dropouts was compared with those of
patients who remained in the study for 5 years.
STATISTICAL ANALYSIS
The study was powered to detect a 5% change in FEV1
(power 80%, significance level 5%). The minimum sample
size thus estimated was 64 pairs.
Apart from airway responsiveness, all other outcome
variables are reported as mean values with a 95% confi-
dence interval. Differences between the groups were tested
in all variables at baseline and at 5 years with Student’s
independent samples t-test. Due to the skewed distributions
of cost variables, their medians were calculated and the
non-parametric Mann-Whitney U-test was also used for
analysing differences between the groups in costs.
Differences in outcome variables between baseline and
the 5-year follow-up within the groups were tested with the
paired t-test.
The unscheduled healthcare costs were grouped into
quartiles and the difference between the groups tested by
w2-test. A P-value of 50?05 was considered significant.
Results
BASELINE CHARACTERISTICS
The groups did not differ at baseline in any parameter so
the randomization was successful. The baseline character-istics of the 64 patients in the IG and 70 patients in the
CG who were present at the 5-year follow-up did not
differ significantly. Details of patients present both at
baseline and 5-year follow-up are described in Table 1. The
current IG smokers had 6?9 (95% CI 4?25; 9?48) mean pack
years at baseline and the CG smokers 8?4 (95% CI 5?75;
11?13), and at 5 years 10?1 (95% CI 4?8; 15?4) and 12?6
(95% CI 8?4; 16?9), respectively. The differences were not
significant.
The data on the bought drugs were obtained from the
Finnish Social Insurance Institution for 137 patients, of
whom 118 were present at the 5-year analysis. Ten patients
did not answer the permission request letter and there was
no information on the remaining nine patients in the
Finnish Social Insurance Institution’s purchase of asthma
drugs files, either because their drugs were paid for by their
private or occupational insurance or the pharmacies
involved were not computerized.
DROPOUTS
Five patients in the IG missed all the control visits after the
baseline. Of the other 11 patients who missed at least one of
the control visits, four patients had moved away and seven
were unwilling to attend, mostly due to being without
symptoms. The only significant difference in baseline
parameters between the 16 dropouts and the 64 patients
remaining in the study for 5 years was gender: 14 of the
dropouts were women, P = 0?045.
The dropouts in the CG included one patient who died in
a trac accident after the baseline visit. Eleven patients
missed one of the later control visits: one died of coronary
heart disease, four moved away and six failed to make
contact. The dropouts in the IG and the CG did not differ
in any baseline parameter.
Bronchial hyperresponsiveness could not be tested in
four IG patients: three were pregnant and one had a low
FEV1 value; nor could it be tested in four CG patients: one
was pregnant and three had a low FEV1 value.
The dropouts from both groups had a better baseline
HRQOL score as measured by both the 15D and SGRQ
than the patients remaining until 5 years, although the
differences were not significant in either group (P = 0?1).
The costs of the dropouts were not included when
calculating the mean total 5-year costs. The mean annual
costs of dropouts did not differ significantly from those of
remaining patients.
OUTCOME MEASURES
Results within the groups
Apart from FVC, all lung function parameters improved
significantly in the IG between baseline and 5-year follow-
up. The improvement in mean FEV1 was 3?3% units, P =
0?04 (Table 2 and Fig. 2). Only PEF and FEV% improved
significantly in the CG (Table 2). The improvements in lung
function of the smokers did not differ significantly from
those of non-smokers in either group.
TABLE 1. Baseline characteristics of all patients and of those included in the 5-year control (SD in parentheses). There were no
significant differences between the groups
Intervention Control
All patients Included All patients Included
at 5 years at 5 years
n=80 n=64 n=82 n=70
Sex (M/F) 25/55 25/39 35/47 27/43
Mean age years (range) 43?1 (18–76) 43?9 (18–76) 44?2 (19–76) 44?7 (19–76)
Atopy* 52 38 39 35
Current smokers 19 9 16 11
FVC (% of predicted) 95?1 (12?5) 94?5 (12?6) 92?5 (14?8) 92?5 (14?5)
FEV1 (% predicted) 86?1 (14?0) 85?0 (13?5) 82?8 (14?8) 82?9 (14?6)
FEV1/FVC 90?0 (10?0) 89?4 (9?7) 89?1 (9?7) 89?2 (9?6)
PEF 84?3 (11?4) 83?7 (11?4) 83?4 (13?5) 83.3 (13.2)
PD15 dose step 0?54 (0?09) 0?56 (0?09) 0?58 (0?09) 0?59 (0?08)
15D score 0?89 (0?10) 0?89 (0?09) 0?89 (0?10) 0?89 (0?10)
SGRQ total score 27?0 (14?6) 26?8 (14?0) 27?7 (15?6) 27?8 (16?4)
Treatment:
inhaled corticosteroid 75 64 77 69
nedocromil 5 0 5 1
*at least one positive skin-prick test reaction to 10 common allergens.
PD15: bronchial hyperresponsiveness in dose steps; PEF: peak expiratory flow; 15D: generic 15 dimensions quality-of-life
instrument; SRGQ: St. George’s Respiratory Questionnaire, disease-specific quality-of-life instrument.
PATIENT EDUCATION IN NEWLY DIAGNOSED ADULT ASTHMA 59Due to a skewed distribution the geometric mean was
first calculated for airway responsiveness in mg ml71
histamine. This logarithmic transformation did not correct
the skewness. Therefore the changes in airway responsive-
ness using the step doses were calculated, which were
almost normally distributed. They better describe the
change in hyperreactivity.
Bronchial hyperresponsiveness improved in both groups
significantly over the 5-year period (P = 0?000) (Table 3
and Fig. 3). One IG patient at baseline and 23 patients
(38?3% from tested patients) at 5 years had a normal level
of PD15^1.6mg compared to two and 18 patients (27?3%),
respectively, in the CG.
The disease-specific and generic HRQOL scores im-
proved significantly in both groups. The mean SGRQ score
improved by 12?0 units in the IG and 14?1 units in the CG.
The mean 15D score improved by 0?04 units in both the IG
and the CG (Tables 2 and 3). The mean AQ20 scores were
4?4 points in the IG and 5?5 in the CG. The linear
correlation of the short SGRQ (AQ20) scores with the
ordinary SGRQ total scores and 15D scores was good: r=
0?86 and r = 0?78, respectively.
Differences between the groups
There were no significant differences between the groups in
lung functions, bronchial hyperresponsiveness or in
HRQOL scores at 5 years.
The IG patients experienced 152 (range 0–17) sickness
days due to asthma during the 5 years and the CG patients398 (range 0–90), (P = 0?07). The relative risk for sickness
days was significantly lower in the IG than in the CG, odds
ratio 0?33 (95% CI 0?28; 0?40).
When compliance was assessed on the basis of the use of
PEF-based self-management, 35 patients in the IG and 23
in the CG used PEF and made recordings according to the
advice given, this difference being significant P = 0?005.
None of the outcome measures differed significantly
between the patients who used PEF-based or symptom-
based self-management. There was no difference between
the two groups.
COSTS
The mean total 5-year costs without drug costs were £840 in
the IG (direct £421 + indirect £198 + intervention costs
£220) and £957 in the CG (direct £467 + indirect £490).
The differences between the groups were not statistically
significant (Table 4). The unscheduled healthcare costs were
£164 in the IG and £261 in the CG, the difference is
significant (w2 = 9?5, df = 3, P = 0?02).
The mean cost of bought anti-asthma drugs over 4 years
was £803 per patient in the IG, and £1064 per patient in the
CG. The difference between the groups was not significant
(Table 4).
The average total cost over the 5 years was £1906 in the
IG and £2287 in the CG (the average net monetary benefit
was £381). The difference was not statistically significant at
the conventional levels (Table 4). The conclusion remained
TABLE 2. The mean values of lung functions (percentage of
predicted), bronchial hyperresponsiveness in dose steps
(PD15) and health-related quality-of-life scores from base-
line to 5-year follow-up (95% CI in parentheses). There
were no significant differences between the groups
Intervention
n = 64
Control
n = 70
FVC 1?0 70?3
(74?1; 1?9) (73?3; 2?7)
FEV1 3.3* 1?8
(0?2; 6?4) (71?3; 5?0)
FEV% 3?1** 3?0***
(1?1; 5?1) (1?2; 4?7)
PEF 7?2*** 4?6**
(4?6; 9?6) (1?9; 7?4)
PD15 1?4*** 1?0***
dose step (1?0; 1?5) (0?8; 1?4)
15D 0?04*** 0?04***
(0?02; 0?05) (0?02; 0?05)
SGRQtot 12?0*** 14?1***
(8?3; 14?8) (10?8; 17?0)
Significance of difference between baseline and 5-year
follow-up within the groups, paired sample t-test:
*P50?05, **P50?01, ***P50?001, means that the value
deteriorated from the baseline level. FEV%: FEV1/FVC,
PD15: bronchial hyperresponsiveness in dose steps; PEF:
peak expiratory flow; 15D: generic quality of life instru-
ment; SRGQ: St. George’s Respiratory Questionnaire,
disease-specific quality-of-life instrument, total score.
FIG. 2. The mean FEV1 over the 5-year follow-up in the
intervention and control group. There was a significant
improvement in the intervention group from baseline over
5 years. In the control group there was no significant
change over 5 years. The only statistically significant
difference between the groups was at one year, P = 0?02.
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and £457 per patient in the CG, of which 56% was used for
drugs in the IG and 58% in the CG (Fig. 4).
Discussion
The intensive patient education for self-management
among newly-diagnosed asthmatics did not increase the
total treatment costs. The intervention had a consistent
tendency of being less costly than the conventional
programme, but this conclusion is shadowed by uncertainty
beyond conventional levels of statistical significance.
When only unscheduled healthcare costs were consid-
ered, there was a significant difference between the groups
in favour of the IG. This difference is explained mainly by
fewer unscheduled visits to healthcare centres. The asth-
matics in both groups needed surprisingly little hospital and
emergency department services, only four patients, one
twice, visited the emergency department. In Finland, mild
asthmatic patients usually first visit a general practitioner if
they have problems with their asthma.
The patients in the IG had a significantly lower risk for
sickness days during the whole follow-up period. Trautner
et al. (23) also found a decrease in the loss of productivity in
their 3-year follow-up study among 132 moderate or severe
asthmatics. Also the study of Lahdensuo et al. (1) among
122 mild to severe asthmatics showed a similar result,
although their follow-up time was only 12 months.
The FEV1 improved only in the IG, 3?3% units from
baseline to 5 years. One reason for this minor improvement
might be that the FEV1 was already normal at baseline,
85?0% from predicted value among the evaluated IG
patients. Undoubtedly the patients’ mild asthma according
to FEV1 is reflected in the results. Maybe a bigger sample
size would have been needed to find a difference between
the groups. The FEV1 decreased from the first year’s level
(Fig. 2). It is noteworthy that the obstruction improved
only during the first year, but the hyperreactivity continued
to improve slowly during the follow-up. In the CG, the
airway obstruction did not improve significantly. However,
the lower treatment effectiveness in terms of airway
hyperresponsiveness improved during the two last years
of the follow-up (Fig. 3). Effective treatment during the first
few years seemed to be more crucial for the improvement of
airway obstruction than for the hyper-responsiveness.
To the authors knowledge no published study has
reported a 5-year follow-up of bronchial hyperreactivity
for newly-diagnosed asthmatics. The improvement of
hyperresponsiveness in the present study was roughly the
same as that achieved by van Essen-Zandvlier et al. (24) in
their 22–36 month follow-up study. About 13% of children
with asthma (n=58) treated with inhaled corticosteroid
improved to a normal value. Boulet et al. (25) found in their
5-year follow-up study among 40 mild or moderate
asthmatics that the change in hyperreactivity was mini-
mally influenced by the duration of asthma and age at the
time of diagnosis. Improvement was greater among atopics
and after regular use of inhaled corticosteroids.when the costs were discounted at 3% (£1728 and £2072,
respectively) or at 6% (£1572 and £1887, respectively).
Since there was no significant difference between the
groups either in any outcome variable or in total costs
(including 5-year drug costs) at 5 years, no incremental
cost-effectiveness ratio could be calculated.
FIG. 3. The mean histamindose steps þ/7 SEM in the
intervention and control groups over the 5 year follow-up.
In the intervention group (IG) there was a significant
improvement from baseline to 1, 3 and 5 years (P= 0?000).
In the control group (CG) there were significant
improvements in PD15 from baseline to 1 year (P = 0?000)
and from 3 to 5 years, P = 0?004. The only statistically
significant difference between the groups was at 3 years in
terms of improvement in dose steps, P = 0?04.
TABLE 3. The mean scores for values of lung functions (percentage of predicted), bronchial hyperresponsiveness in dose steps
(PD15) and health-related quality of life of patients included both at baseline and 5-year follow-up (95% CI in parentheses).
There were no significant differences between the groups
Intervention Control
At baseline At 5 years At baseline At 5 years
n = 64 n = 64 n = 70 n = 70
FVC 94?5 95?6 92?5 92?2
(91?4; 97?7) (92?1; 99?0) (89?1; 95?9) (89?3; 95?2)
FEV1 85?0 88?3 82?9 84?7
(81?7; 88.4) (84?6; 92?1) (79?5; 86?4) (81?7; 87?8)
FEV% 89?4 92?5 89?2 92?1
(87?0; 91?8) (90?1; 94?3) (86?9; 91?4) (90?0; 94?3)
PEF 83?7 90?8 83?3 88?0
(80?8; 86?5) (87?5; 94?1) (80?2; 86?5) (84?9; 91?0)
PD15 0?56 1. 92 0?59 1.59
dose step (0?38; 0?74) (1?66; 2?18) (0?37; 0?75) (1?32; 1.86)
15D 0?89 0?93 0?89 0?93
(0?87; 0?91) (0?91; 0?94) (0?86; 0?91) (0?91; 0?95)
SGRQtot 27?0 15?0 27?7 13?6
(23?2; 30?3) (12?0; 18?0) (23?8; 31?7) (10?8; 16?4)
FEV%: FEV1/FVC; PD15: bronchial hyperresponsiveness in dose step; 15D: generic quality-of-life instrument; SRGQ: St.
George’s Respiratory Questionnaire, disease-specific quality-of-life instrument, total score.
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at least as important as patient education in terms of better
treatment results, as Chapman pointed out in his review
article (9). According to the literature it is unclear whether
earlier improvement in bronchial hyperresponsiveness
shows later benefit clinically or economically (26). A
shortage of studies with long-term economic evaluation
among newly-diagnosed asthmatics made the comparison
of these results dicult.The PEF-based self-management had no advantage over
the symptom-based approach in the present study although
significantly more patients in the IG than in the CG had
adopted the use of a PEF-meter in the long-term. The long-
term follow-up result agreed with that of Ayres et al. (27),
Charlton et al. (4) and Cote´ et al. (28) with 1-year follow-up
and that of Turner et al. (8) with 6 months of follow-up.
They found that PEF-based self-management was no more
effective than a symptom-based approach and PEF-based
self-management alone had a minor effect on the treatment
result in mild asthma. However, the significantly lower risk
for sickness days without a difference in the costs of the
anti-asthma drugs used might mean that the IG patients
had assimilated the self-management better and were able
to adjust their use of anti-inflammatory drugs according to
actual need.
It is also tempting to speculate that one reason for the
present findings might be more stable drug consumption in
the IG, while the CG patients might have more fluctuation
or even interruption in their asthma anti-inflammatory
treatment. The results agreed with the 12-month study of
Neri et al. (3). They showed that a key feature of an asthma
programme was proper treatment and regular supervision.
The importance of medication was also discovered in the
self-management studies with 12 months of follow-up
among moderate and severe asthmatics by Wilson et al.
(29) (n=323), Allen et al. (30) (n=116) and Cote´ et al.
(28) (n=188). They achieved similar clinical outcomes
through the provision of optimal asthma-medication
management compared to intensive short-term patient
education. They did not conduct an economic evaluation.
TABLE 4. The mean direct, indirect and total costs (£) of treatment in the intervention and control group over the 5-year
follow-up, and the costs of 4 years of regular drug treatment (range and quartiles in around median in parentheses). There
were no significant differences between the groups
Intervention Control
Mean Median Mean Median
Direct costs without 516* 408* 467 357
drug costs (383–2074) (383–518) (258–1624) (258–537)
Indirect costs 323* 144* 490 56
(141–2406) (141–200) (46–7166) (46–612)
Total costs without 840* 559 957 494
drug costs (523–4467) (523–902) (303–7554) (303–1175)
Drug costs in 4 years 803 739 1064 787
(6–2816) (341–1213) (0–72623) (546–1244)
Total costs including 1906* 1727* 2286 1640
5-year drug costs (726–7506) (1319–2241) (636–9842) (1283–2668)
*Includes intervention costs: direct £125; indirect £95, 1£ = 9.0 Finnish marks (FIM). The costs of diagnosis and
randomization were not included.
FIG. 4. The distribution of total treatment costs among
newly diagnosed asthmatics over the 5-year follow-up (n
= 134). (a) intervention group; (b) control group.
: direct £; : drugs £; : indirect £;
62 R. KAUPPINEN ET AL.Thus the regular use of anti-asthmatic medication might be
more important for improving outcome than the adoption
of a self-management plan also for the newly-diagnosed
asthmatics, at least during the first 5 years.
The quality of life of newly-diagnosed asthmatics improved
significantly in both groups according to both the generic and
disease-specific HRQOL instrument. It is worth noting that in
terms of HRQOL change the most important treatment
period was the first year (11,12). The AQ20 scores correlated
well with the original SGRQ scores and 15D scores. The
AQ20 score was easy to calculate from the number of ‘yes’
answers. It was also easy to use the AQ20 in normal clinical
practice and it was also possible to use it to evaluate patients’
own opinion of treatment effects and problems.
The intensive patient education for self-management
during the first treatment year may lead to lower long-term
costs, since regardless of which cost item was looked at
there was a consistent tendency for the cost to be lower in
the IG. However, it was not possible to define a formal
incremental cost-effectiveness ratio, since there was no
statistically significant difference between the groups in anyof the outcome variables at 5 years. The reduced need for
unscheduled health services and sickness days without
worse outcome indicated better self-management skills. The
intervention had a positive effect on airway hyperrespon-
siveness and FEV1 over the first 3 years, but after the
control visit at 3 years the differences between the groups
disappeared. It is possible to tentatively conclude that
regular effective medical treatment and control visits during
the first years were at least as important for the long-term
treatment result as intensive patient education. This result
stresses a need to study the importance of the follow-up
visits to improve the treatment effectiveness. There is also
need for further research among newly-diagnosed asth-
matics concerning the cost-effectiveness of treatment
follow-ups arranged in specialist outpatient clinics or in
primary healthcare centres.
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